PPIP5K1 and early-onset autosomal dominant Alzheimer disease: The importance of IP6K in these processes has led to interest in the development of IP6K inhibitors with potential therapeutic value in diseases including diabetes, obesity, fatty liver disease, chronic kidney disease, osteoporosis, cancer, thrombosis, hyperphosphatemia, mood disorders, and Alzheimer’s disease [24,32,33,34,35].